The College of Medicine and Veterinary Medicine at The University of Edinburgh is an international leader in basic-to-clinical translational research.
Our approach ranges from molecules to man, from bench to bedside, and from process to population. Our interdisciplinary groups, centres and institutes bring together basic and clinical academic staff in broad, thematic research concentrations encompassing basic sciences, translational and clinical research. Research within the College explicitly links biomedicine and veterinary medicine, in promotion of the concept 'One Medicine'.
High calibre graduates are invited to apply for funded PhDs for September 2018 entry across our world-leading research institutes, centres and doctoral training programmes. Our research areas include:
In our Interdisciplinary Research Centres, critical masses of clinical and basic scientists interact closely around their basic-to-translational goals, overcoming boundaries between "wet" and "dry" science and primary and secondary care, adding substantial value and offering the finest research training environments.
The excellence of these Centres is evidenced by prestigious external funding awards including: 4 Medical Research Council (MRC) Centres, 2 British Heart Foundation (BHF) Centres, a Cancer Research UK (CRUK) Centre, an Asthma UK (A-UK) Centre for Applied Research, a BBSRC Strategically funded institute (The Roslin Institute), an MRC University Unit (Human Genetics Unit) and a World Health Organisation (WHO) Collaborating Centre on Population Health Research and Training. In addition to these, the Wellcome Trust has just awarded funding for 4 year PhDs in Translational Neuroscience and Tissue Repair.
The University of Edinburgh is a leading postgraduate teaching and research centre, ranked 19th in the QS World Rankings 2016/17, 7th in Europe, 5th in the UK and 1st in Scotland.
The College’s reputation as one of the world’s leading centres of medical and veterinary medical research has been reaffirmed by its UK REF 2014 results.
The deadline for the majority of PhD Studentships for 2017/18 entry is end of January 2018 - we usually start accepting applications for these funded PhDs in late autumn (November/December). Please visit each Research Centre website (listed above) and live PhD projects (listed below) for specific deadlines.
|Exploring and Exploiting C. elegans to identify PINK1/Parkin regulatory circuits in vivo that are important for Parkinson’s disease||Details|
|Exploring the uses of digital data in in commercial settings and extracting potentially transferable lessons for healthcare||Details|
|Fluorescent chemical probes for imaging immune cells in the tumour microenvironment||Details|
|Identification of the cell of origin in MLL-AF9-associated infant leukaemia||Details|
|Improving the precision of radiotherapy in gliomas by advanced imaging and image analysis||Details|
|Innate antimicrobial host defence peptides as protective modifiers in atopic dermatitis||Details|
|Innate modification of Th17 cell behaviour during Multiple Sclerosis||Details|
|Investigation of LRRK2 and PINK1 signalling in midbrain dopaminergic neurons derived from human pluripotent stem cells||Details|
|Longitudinal monitoring of Parkinson’s disease symptom progression using patient reported outcome measures, clinical assessments, and non-invasive sensors||Details|
|Molecular mechanisms regulating autophagy and immunogenicity in pancreatic and lung cancer||Details|
|Population genomics of Staphylococcus aureus associated with human and animal diseases||Details|
|Predicting the conversion of LRRK2 carriers to Parkinson disease: the role of blood and CSF biomarkers||Details|
|The role of tumour microenvironment in hormone refractory prostate cancer.||Details|
|Understanding Colorectal Cancer risk loci that alter transcriptional dynamics.||Details|
|What is the relationship between LRRK2 kinase activity and α-synuclein aggregation and pathogenicity in human midbrain dopaminergic neurons?||Details|